Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Logothetis

Showing results (71-80 of 251) with videos related to

Pageof 26
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancerEleni Efstathiou, Patricia Troncoso, Sijin Wen, et al.
The Prostate|March 30, 2012
Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118bMaria Karlou, Jing-Fang Lu, Guanglin Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2002
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostateChristos N Papandreou, Danai D Daliani, Peter F Thall, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 29, 2021
Enhancing <sup>223</sup>Ra Treatment Efficacy by Anti-<b>β</b>1 Integrin TargetingClaudia Paindelli, Stefano Casarin, Feng Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2003
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancerRandall Millikan, Peter F Thall, Sang-Joon Lee, et al.
Carcinogenesis|August 13, 2016
Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillanceXiang Shu, Yuanqing Ye, Jian Gu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancerArlene O Siefker-Radtke, Randall E Millikan, Shi-Ming Tu, et al.
The Prostate|July 4, 2012
Integrated Hedgehog signaling is induced following castration in human and murine prostate cancersEleni Efstathiou, Maria Karlou, Sijin Wen, et al.
Anticancer Research|November 3, 2004
High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancerKarim Fizazi, Charles R Sikes, Jeri Kim, et al.
The Journal of Urology|December 11, 2003
Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experienceArlene O Siefker-Radtke, Garrett L Walsh, Louis L Pisters, et al.
Pageof 26

Showing results (71-80 of 251) with videos related to

Sort By:
Pageof 26
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancerEleni Efstathiou, Patricia Troncoso, Sijin Wen, et al.
The Prostate|March 30, 2012
Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118bMaria Karlou, Jing-Fang Lu, Guanglin Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2002
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostateChristos N Papandreou, Danai D Daliani, Peter F Thall, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 29, 2021
Enhancing <sup>223</sup>Ra Treatment Efficacy by Anti-<b>β</b>1 Integrin TargetingClaudia Paindelli, Stefano Casarin, Feng Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2003
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancerRandall Millikan, Peter F Thall, Sang-Joon Lee, et al.
Carcinogenesis|August 13, 2016
Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillanceXiang Shu, Yuanqing Ye, Jian Gu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancerArlene O Siefker-Radtke, Randall E Millikan, Shi-Ming Tu, et al.
The Prostate|July 4, 2012
Integrated Hedgehog signaling is induced following castration in human and murine prostate cancersEleni Efstathiou, Maria Karlou, Sijin Wen, et al.
Anticancer Research|November 3, 2004
High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancerKarim Fizazi, Charles R Sikes, Jeri Kim, et al.
The Journal of Urology|December 11, 2003
Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experienceArlene O Siefker-Radtke, Garrett L Walsh, Louis L Pisters, et al.
Pageof 26